Literature DB >> 9862587

Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases.

S M Green1, S G Rothrock, T Harris, G A Hopkins, W Garrett, T Sherwin.   

Abstract

OBJECTIVES: To determine the safety of i.v. ketamine when administered by emergency physicians (EPs) for pediatric procedures, and to contrast the sedation characteristics of the i.v. and i.m. routes.
METHODS: The study was a retrospective consecutive case series of children aged < or =15 years given i.v. ketamine in the EDs of a university medical center and an affiliated county hospital over a 9-year period. A protocol for ketamine was used by treating physicians. Records were reviewed for adverse effects, indication, dosing, adjunctive drugs, inadequate sedation, and time to release. Results were contrasted with previously reported data for the i.m. route.
RESULTS: During the study period i.v. ketamine was administered 156 times, primarily for laceration repair and fracture reduction. Transient apnea and respiratory depression occurred in one patient each; both were quickly identified and were without sequelae. Laryngospasm or aspiration was not noted in any children. There were 6 children with emesis and 2 with mild agitation during recovery. The median time from initial dose to ED release was 103 minutes (25th to 75th percentiles 76 to 146 minutes). The i.v. and i.m. routes were comparable in terms of adverse effects, inadequate sedation, and time to release.
CONCLUSION: I.v. ketamine can be administered safely by EPs to facilitate pediatric procedures when used in a defined protocol. The sedation characteristics of the i.v. and i.m. routes appear comparable.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862587     DOI: 10.1111/j.1553-2712.1998.tb02773.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  29 in total

Review 1.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Comparison of ketamine and ketofol for deep sedation and analgesia in children undergoing laser procedure.

Authors:  Marija Stevic; Nina Ristic; Ivana Budic; Nebojsa Ladjevic; Branislav Trifunovic; Ivan Rakic; Marko Majstorovic; Ivana Burazor; Dusica Simic
Journal:  Lasers Med Sci       Date:  2017-07-12       Impact factor: 3.161

Review 3.  Glutamatergic Modulators in Depression.

Authors:  Ioline D Henter; Rafael Teixeira de Sousa; Carlos A Zarate
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

4.  Rapid administration technique of ketamine for pediatric forearm fracture reduction: a dose-finding study.

Authors:  Sri S Chinta; Charles R Schrock; John D McAllister; David M Jaffe; Jingxia Liu; Robert M Kennedy
Journal:  Ann Emerg Med       Date:  2015-01-14       Impact factor: 5.721

5.  Predictors of emesis in children undergoing procedural sedation with intramuscular ketamine in a paediatric emergency department.

Authors:  Shruthi Suryaprakash; Lai Peng Tham
Journal:  Singapore Med J       Date:  2016-12-09       Impact factor: 1.858

Review 6.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Pediatric procedural sedation and analgesia.

Authors:  James R Meredith; Kelly P O'Keefe; Sagar Galwankar
Journal:  J Emerg Trauma Shock       Date:  2008-07

Review 8.  Ketamine for paediatric sedation/analgesia in the emergency department.

Authors:  M C Howes
Journal:  Emerg Med J       Date:  2004-05       Impact factor: 2.740

9.  The Lancaster experience of 2.0 to 2.5 mg/kg intramuscular ketamine for paediatric sedation: 501 cases and analysis.

Authors:  R G McGlone; M C Howes; M Joshi
Journal:  Emerg Med J       Date:  2004-05       Impact factor: 2.740

Review 10.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.